<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131365</url>
  </required_header>
  <id_info>
    <org_study_id>UF014 - 4.1/3T</org_study_id>
    <nct_id>NCT00131365</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids</brief_title>
  <official_title>Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <brief_summary>
    <textblock>
      The goal of this study is to develop additional long term data to evaluate the safety and&#xD;
      effectiveness of this treatment.&#xD;
&#xD;
      Indications for use for this system is: 'The ExAblate is intended to ablate uterine fibroid&#xD;
      tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a&#xD;
      uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not&#xD;
      seeking treatment for reasons of improving fertility.'&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      General:&#xD;
&#xD;
      Uterine leiomyoma (fibroids) are the most common neoplasms of the female pelvis. These benign&#xD;
      tumors are generally oval in shape, and often highly vascular. On T2 weighted MR imaging&#xD;
      exams, or T1 exams with contrast, uterine fibroids are easily identifiable. They occur in&#xD;
      20-25% of women of reproductive age and can cause a variety of problems generally described&#xD;
      as either bleeding or mass effects from the fibroid. In general, these symptoms can be&#xD;
      classified into two categories:&#xD;
&#xD;
        1. heavy menstrual bleeding, defined as bleeding on heavy days requiring a change of&#xD;
           sanitary wear every 2 hours or less, significant clot passage, flooding, substantial&#xD;
           prolongation of menstrual periods compared with the patient's prior experience, or&#xD;
           anemia.&#xD;
&#xD;
        2. pelvic pain or pressure, heaviness or discomfort, or similar symptoms in the back, flank&#xD;
           or leg attributable to the bulk of the fibroid, urinary frequency, increase in nocturia,&#xD;
           difficulty voiding or compression of the ureters with hydronephrosis.&#xD;
&#xD;
      Measures of the clinical success of patients who elect treatment of fibroids are generally&#xD;
      subjective, and evaluated by the patient in terms of improvement in the initial symptoms that&#xD;
      caused her to seek treatment (decrease in pain, bladder or bowel symptoms, or reduction in&#xD;
      vaginal bleeding), while experiencing a minimum of co-morbidities from the treatment itself.&#xD;
&#xD;
      ExAblate Device:&#xD;
&#xD;
      The InSightec ExAblate MR guided Focused Ultrasound Surgery (MRgFUS) system is a non-invasive&#xD;
      thermal ablation device fully integrated with an MR imaging system and used for the ablation&#xD;
      of soft tissue. It has been evaluated in an earlier FDA international, multi-center study and&#xD;
      found to be safe and effective for the treatment of uterine fibroids. ExAblate device&#xD;
      received FDA approval in October 2004.&#xD;
&#xD;
      Prior Studies:&#xD;
&#xD;
      The ExAblate has been used for the treatment of uterine fibroids in 2 previous IDE protocols.&#xD;
&#xD;
        -  Group A: This was the original Pivotal Study Group (IDE G020001 - Protocol UF002). These&#xD;
           109 patients were treated at 3 sites in the US and at 4 sites outside the US. There was&#xD;
           a limitation on the allowable treatment volume and only a single treatment was&#xD;
           permitted. Original follow-up was planned for 6 months. The study was later extended to&#xD;
           include follow-up visits at 12, 24, and 36 months (UF009). Because of the gap between&#xD;
           the initial study consent, and the re-consent for the long term follow-up there was a&#xD;
           high dropout rate at the 12 month visit. Thirty-three US patients returned for the 12&#xD;
           months visit, and will continue to be followed for the 24 and 36 M visits.&#xD;
&#xD;
        -  Group B: This was the Continued Access Study (IDE G020001 - Protocol UF005) where&#xD;
           approximately 160 patients were treated at 3 sites in the US during the PMA review&#xD;
           period. Treatment conditions were modified somewhat from the pivotal, including the&#xD;
           addition of a second treatment session where necessary. The initial study was planned to&#xD;
           include a long term follow-up of 12, 24 and 36 months (UF009).&#xD;
&#xD;
        -  Group C: This group of 70 patients (UF14) will be treated post-PMA approval following&#xD;
           the commercial treatment guidelines. The follow-up will include for visits at 12, 24 and&#xD;
           36 months. This group includes also another 20 patients who will be treated under this&#xD;
           original IDE to validate the ExAblate system for use in a 3T MR scanner, as well as&#xD;
           validating a new application SW (V4.1).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Type of Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Adverse events outcomes are reported in the adverse events module.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>ExAblate MRgFUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the ExAblate 2000 system Version 4.1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate 2000</intervention_name>
    <arm_group_label>ExAblate MRgFUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who present with symptomatic uterine fibroids and are not seeking treatment for&#xD;
             the reason of improving fertility.&#xD;
&#xD;
          -  Able and willing to give consent and able to attend all study visits.&#xD;
&#xD;
          -  Patient is pre or peri-menopausal (within 12 months of last menstrual period).&#xD;
&#xD;
          -  Able to communicate sensations during the ExAblate procedure.&#xD;
&#xD;
          -  Uterine fibroids, which are device accessible (i.e., positioned in the uterus such&#xD;
             that they can be accessed without being shielded by bowel or bone).&#xD;
&#xD;
          -  Fibroids(s) clearly visible on non-contrast magnetic resonance imaging (MRI).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metallic implants that are incompatible with MRI&#xD;
&#xD;
          -  Sensitive to MRI contrast agents&#xD;
&#xD;
          -  Severe claustrophobia that would prevent completion of procedure in MR unit&#xD;
&#xD;
          -  Women who are pregnant or desire to become pregnant in the future. Pregnancies&#xD;
             following ExAblate treatment could be dangerous for both mother and fetus.&#xD;
&#xD;
          -  Pedunculated fibroids&#xD;
&#xD;
          -  Active pelvic inflammatory disease (PID)&#xD;
&#xD;
          -  Active local or systemic infection&#xD;
&#xD;
          -  Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and&#xD;
             adenomatous hyperplasia&#xD;
&#xD;
          -  Intrauterine device (IUD) anywhere in the treatment path&#xD;
&#xD;
          -  Dermoid cyst of the ovary anywhere in the treatment path&#xD;
&#xD;
          -  Extensive abdominal scarring that cannot be avoided by redirection of the beam (e.g.,&#xD;
             due to Caesarean section or repeated abdominal surgeries)&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Min, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell Vascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cornell Vascular</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Sponsor home page</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 17, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <results_first_submitted>March 5, 2019</results_first_submitted>
  <results_first_submitted_qc>May 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2019</results_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibroids</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>ExAblate</keyword>
  <keyword>MrgFUS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The protocol was approved to enroll 20 participants; however, due to the obsolescence of device features the study was closed after enrolling 9 participants.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ExAblate MRgFUS</title>
          <description>Treatment with the ExAblate 2000 system Version 4.1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">Only safety data was reported due to early closure of the study due to device obsolescence.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ExAblate MRgFUS</title>
          <description>Treatment with the ExAblate 2000 system Version 4.1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age data was not collected</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>not collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">age data was not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Type of Adverse Events</title>
        <description>Adverse events outcomes are reported in the adverse events module.</description>
        <time_frame>36 months</time_frame>
        <population>Adverse events outcomes are reported in the adverse events module.</population>
        <group_list>
          <group group_id="O1">
            <title>ExAblate MRgFUS</title>
            <description>Treatment with the ExAblate 2000 system Version 4.1&#xD;
ExAblate 2000</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Type of Adverse Events</title>
          <description>Adverse events outcomes are reported in the adverse events module.</description>
          <population>Adverse events outcomes are reported in the adverse events module.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Adverse events outcomes are reported in the adverse events module.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ExAblate MRgFUS</title>
            <description>Treatment with the ExAblate 2000 system Version 4.1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Adverse events outcomes are reported in the adverse events module.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ExAblate MRgFUS</title>
          <description>Treatment with the ExAblate 2000 system Version 4.1&#xD;
ExAblate 2000</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anal irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Foley catheter urethral irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back pain - positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Leg/back pain - sonication induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain - sonication related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was closed to enrollment in 2005 due to obsolescence of device features. Only safety data on the 9 enrolled participants was reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nadir Alikacem</name_or_title>
      <organization>InSightec</organization>
      <phone>214.630.2000</phone>
      <email>nadira@insightec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

